The approval was based on improved overall and PFS with irinotecan liposome alongside oxaliplatin, fluorouracil, and leucovorin vs gemcitabine plus nab-paclitaxel.
Liposomal irinotecan plus chemo in the new NALIRIFOX regimen significantly improved overall survival compared with standard therapy in metastatic pancreatic ductal adenocarcinoma.
Women with polycystic ovary syndrome (PCOS) may be at a higher risk of developing pancreatic cancer, say researchers reporting an association between the two.
The latest Annual Report to the Nation on the Status of Cancer notes that deaths from the disease have been falling by 2% from 2014 to 2019; the biggest decreases were in lung cancer and melanoma.